Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial

Chi K.N.¹ , Gleave M. ¹ , Higano C.S.² , Blumenstein B.³ , Ferrero J.M.⁴ , Reeves J.⁵ , Feyerabend S. ⁶ , Stenzl A.⁷ , Gravis G. ⁸ , Merseburger A.S.⁹ , Bergman A.M.¹⁰ , Mukherjee S.D.¹¹ , Zalewski P.¹² , Saad F. ¹³ , Jacobs C.¹⁴ , De Bono J.S.¹⁵

The Lancet Oncology

4

English

473-485

Published

18

2017

• ¹ Department of Medicine|Division of Medical Oncology|University of British Columbia|BC Cancer Agency|Vancouver Prostate Centre
• ² Department of Medicine|Division of Medical Oncology|University of Washington|Fred Hutchinson Cancer Research Center
• ³ Trial Architecture Consulting
• ⁴ Centre Antoine Lacassagne
• ⁵ Florida Cancer Specialists
• ⁶ Department of Urology
• ⁷ University of Tübingen
• ⁸ Institut Paoli Calmette|Department of Cancer Medicine
• ⁹ Department of Urology|University Hospital Schleswig-Holstein
• ¹⁰ Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital
• ¹¹ Juravinski Cancer Centre at Hamilton Health Sciences
• ¹² Durham Regional Cancer Centre
• ¹³ Centre Hospitalier de l'Université de Montréal
• ¹⁴ OncoGenex Pharmaceuticals
• ¹⁵ Drug Development Unit|Royal Marsden Hospital and Institute of Cancer Research

10.07.2024

10.07.2024

https://repository.rudn.ru/en/records/article/record/144462/